IGFBP-7 Marker for Heart Failure Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for heart failure lack reliable biochemical markers for early assessment, leading to late diagnosis and high mortality rates, as existing markers like NT-proBNP have limited positive predictive value for heart failure.
Innovation Solution
The use of insulin-like growth factor binding protein 7 (IGFBP-7) as a marker to assess heart failure, either alone or in combination with other markers, to predict the onset and progression of heart failure, aid in treatment selection, and monitor disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing markers like NT-proBNP are used for heart failure assessment, then the diagnostic method is established and can be implemented, but the positive predictive value is limited and early assessment reliability is insufficient
Solution Approach 1:
The patent combines IGFBP-7 with existing heart failure markers such as NT-proBNP to create a multi-marker diagnostic system. This merging approach allows the new marker IGFBP-7 to complement existing markers, thereby improving overall diagnostic reliability and positive predictive value while maintaining the established diagnostic framework.
Solution Approach 2:
The patent introduces IGFBP-7 as a new biochemical parameter for heart failure assessment. By adding this new marker with different physiological characteristics and detection properties, the system achieves improved measurement precision for early heart failure detection, addressing the limitations of existing single-marker approaches.
2Reliability
If a single marker system is used for heart failure diagnosis, then the diagnostic process is simple and easy to implement, but the predictive value is limited and early detection capability is insufficient
Solution Approach 1:
The patent merges IGFBP-7 with existing heart failure markers to create a multi-marker diagnostic system. This combination approach improves predictive value by leveraging the complementary strengths of different markers while maintaining a relatively simple implementation through standardized assay protocols and integrated testing platforms.
Data Source
AI summary
Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.